Novel_JJ
therapies_NNS
for_IN
inflammatory_JJ
bowel_NN
disease_NN
._.

Looking_VBG
back_RB
at_IN
successes_NNS
and_CC
failures_NNS
in_IN
newer_JJR
approaches_NNS
to_TO
treating_VBG
IBD_NN
,_,
it_PRP
is_VBZ
tempting_JJ
--_:
although_IN
still_RB
difficult_JJ
--_:
to_TO
draw_VB
conclusions_NNS
about_IN
pathogenesis_NN
._.

When_WRB
a_DT
therapy_NN
proves_VBZ
effective_JJ
,_,
do_VBP
clinicians_NNS
truly_RB
know_VB
how_WRB
it_PRP
works_VBZ
?_.

Even_RB
with_IN
a_DT
therapy_NN
as_IN
specific_JJ
as_IN
anti-TNF_JJ
antibody_NN
,_,
it_PRP
is_VBZ
not_RB
clear_JJ
if_IN
the_DT
benefit_NN
is_VBZ
attributable_JJ
to_TO
simple_JJ
binding_NN
and_CC
clearance_NN
of_IN
TNF-alpha_NN
or_CC
to_TO
binding_NN
on_IN
the_DT
cell_NN
surface_NN
and_CC
subsequent_JJ
deletion_NN
of_IN
the_DT
activated_VBN
macrophage_NN
._.

When_WRB
a_DT
drug_NN
appears_VBZ
to_TO
be_VB
less_RBR
effective_JJ
than_IN
preclinical_JJ
models_NNS
suggest_VBP
,_,
can_MD
failures_NNS
in_IN
effectiveness_NN
from_IN
delivery_NN
or_CC
dosing_NN
be_VB
differentiated_VBN
?_.

The_DT
disappointing_JJ
results_NNS
of_IN
clinical_JJ
trials_NNS
with_IN
IL-10_NN
--_:
so_RB
at_IN
odds_NNS
with_IN
the_DT
prediction_NN
of_IN
benefit_NN
from_IN
animal_JJ
models_NNS
--_:
bring_VBP
into_IN
question_NN
the_DT
validity_NN
of_IN
those_DT
models_NNS
as_RB
well_RB
as_IN
the_DT
soundness_NN
of_IN
design_NN
of_IN
the_DT
clinical_JJ
trials_NNS
on_IN
which_WDT
efficacy_NN
of_IN
IL-10_NN
is_VBZ
judged_VBN
._.

The_DT
variability_NN
of_IN
response_NN
even_RB
to_TO
the_DT
most_RBS
narrowly_RB
targeted_VBN
agents_NNS
suggests_VBZ
that_IN
these_DT
diseases_NNS
are_VBP
far_RB
more_RBR
heterogeneous_JJ
in_IN
humans_NNS
than_IN
in_IN
their_PRP$
murine_JJ
counterparts_NNS
._.

Clinicians_NNS
are_VBP
only_RB
just_RB
beginning_JJ
to_TO
recognize_VB
subclinical_JJ
markers_NNS
of_IN
response_NN
,_,
and_CC
it_PRP
may_MD
soon_RB
be_VB
possible_JJ
to_TO
predict_VB
response_NN
on_IN
the_DT
basis_NN
of_IN
genetic_JJ
composition_NN
._.

For_IN
the_DT
moment_NN
,_,
however_RB
,_,
the_DT
field_NN
of_IN
pharmacogenetics_NNS
is_VBZ
embryonic_JJ
._.

Challenges_NNS
in_IN
developing_VBG
new_JJ
therapeutic_JJ
strategies_NNS
include_VBP
not_RB
only_RB
identifying_VBG
novel_JJ
agents_NNS
,_,
but_CC
also_RB
improving_VBG
the_DT
definitions_NNS
of_IN
clinical_JJ
endpoints_NNS
and_CC
defining_VBG
efficacy_NN
at_IN
the_DT
biologic_JJ
level_NN
._.

Only_RB
through_IN
considered_VBN
evaluation_NN
of_IN
clinical_JJ
evidence_NN
may_MD
clinicians_NNS
determine_VB
which_WDT
therapies_NNS
should_MD
remain_VB
novelties_NNS
and_CC
which_WDT
should_MD
become_VB
an_DT
accepted_VBN
part_NN
of_IN
the_DT
armamentarium_NN
._.

